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patterns,	or	topographies,	over	the	course	of	the	disease	(2,	3).		Topographic	studies	of	AD-related	pathology	in	vivo,	until	recently,	have	been	limited	to	fibrillar	Aβ (4,	5)	owing	to	a	lack	of	positron	emission	tomography	(PET)	tau	pathology	imaging	agents.	However,	a	number	of	tau	pathology	imaging	agents	have	recently	been	developed	and	are	available	for	human	studies	(6).				 Extant	models	of	AD	pathophysiology	establish	a	temporal	ordering	of	biomarkers,	with	the	emergence	of	AD-related	tauopathy	occurring	downstream	to	the	accrual	of	Aβ	pathology	(7-11).	Consistent	with	this	proposal,	markers	of	tau	pathology	correlate	more	closely	with	changes	in	cognition	compared	to	Aβ measures	(12).		However,	the	prior	lack	of	imaging	agents	has	limited	studies	of	tau	to	post-mortem	examinations	(13-16)	or	measures	that	lack	topographic	information	(i.e.,	cerebrospinal	fluid	[CSF]).	As	a	result,	relationships	between	cognition	and	Aβ	topography	have	been	defined	(17),	but	the	relationship	with	tau	topography	is	not	defined	in	vivo.	Without	this	spatial	information,	CSF	tau	measures	may	be	assessing	other	forms	of	neurodegeneration	related	to	cell	death	or	synaptic	dysfunction.		The	use	of	both	tau	and	Aβ	imaging	allows	for	the	attribution	of	AD-related	cognitive	dysfunction	to	specific	pathological	process	and	locations	within	the	brain.	Further,	the	spatial	relationships	between	tau	pathology	and	other	biomarkers	of	AD	are	not	established.	This	report	examines	how	tau	imaging	topographies	relate	to	clinical	status,	Aβ	imaging,	CSF	measures	of	AD	pathology,	and	
neuropsychological	performance.	Tau	and	Aβ	represent	distinct	pathological	processes	but	they	are	strongly	related	in	the	context	of	AD.	Given	that	PET-	and	CSF-based	techniques	may	measure	similar	processes	(18),	PET	and	CSF	measurements	of	tau	and	Aβ	are	hypothesized	to	be	related	but	that	relationship	is	likely	stronger	within	specific	topographies.	Next,	the	relationship	between	tau	and	Aβ	imaging	with	cognition	was	assessed.	Given	extant	models	(8,	9)	and	limited	autopsy-based	empirical	data	(13-15)	it	was	hypothesized	that	tau	would	be	a	stronger	predictor	of	cognition	than	Aβ	owing	to	its	place	later	in	preclinical	disease	course.	These	relationships	are	investigated	in	vivo	for	the	first	time	using	multivariate	statistical	models	well	suited	to	identify	PET	topographies	associated	with	presence	or	absence	of	disease,	identify	relationships	between	Aβ	and	tau	pathology	in	distinct	topographies,	and	describe	the	relationship	with	CSF	and	neuropsychological	measures	of	disease.		
Results	Data	from	forty-six	individuals	was	examined.	Global	cognitive	and	functional	performance	was	assessed	by	the	clinical	dementia	rating	(CDR)	(19).	Each	participant	underwent	T807	(tau)	(20)	and	florbetapir	(Aβ)	positron	emission	tomography	(PET)	and	magnetic	resonance	imaging	(MRI).	A	subset	also	underwent	lumbar	puncture	for	CSF	assays	and/or	neuropsychological	testing.	Demographics	of	each	subset	of	the	cohort	are	provided	in	Table	1.	Standardized	uptake	value	ratios	(SUVR)	with	(when	presenting	regional	data)	and	without	(when	presenting	voxelwise	data)	partial	volume	correction	were	calculated	within	42	bilateral	

















Penalized	regression	was	used	to	identify	the	relationship	between	CSF	tau	and	Aβ42	or	neuropsychological	Z	scores,	as	outcome	variables,	and	PET	tau	and	Aβ	topographies	(as	predictors).	The	penalty	in	penalized	regression	is	enforced	against	the	estimated	regression	βs	(26).	The	family	of	penalized	regression	fit	here	is	the	elastic-net	penalty	(27):	the	L1	penalty	component	enforces	sparsity	(i.e.,	many	βs	will	be	identically	0,	not	included	in	the	model)	(26)	while	the	L2	penalty	allows	highly	correlated	variables	to	enter	the	model	simultaneously	(27).	Elastic-net	models	are	well	suited	for	data	that	are	highly	collinear	such	as	regional	PET	data.	Model	parameters	(total	penalty	and	relative	contribution	of	L1	and	L2	penalty)	are	chosen	by	cross-validation.	Penalized	regression	models,	like	any	machine	learning	algorithm,	are	prone	to	overfitting.	To	assess	significance	of	the	fit	models,	permutation	resampling	determined	the	distribution	of	R2	values	under	the	null	hypothesis.	 		Canonical	Correlation	Identifies	Relationships	Between	Tau	and	Aβ	Topographies		 Description	of	the	correlation	between	tau	and	Aβ	topographies	is	accomplished	using	canonical	correlation	(50,	51).	Canonical	correlation	is	the	multivariate	generalization	of	the	more	familiar,	e.g.,	Pearson	bivariate	correlation.	Canonical	correlation	identifies	the	weighted	average	of	ROIs	in	one	distribution	that	is	maximally	correlated	with	another	weighted	average	of	ROIs	in	another	distribution.	The	weighting	vectors,	or	canonical	vectors,	define	topographies.		 	
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	Figure	4:	CSF	and	Neuropsychological	Performance	are	predicted	by	tau	and	Aβ	Topographies.	Each	row	represents	a	single	penalized	regression	model	where	either	CSF	protein	levels	or	neuropsychological	performance	is	predicted.		 𝛽!"# 	and	 𝛽!" 	represent	the	total	predictive	weight	of	tau	and	Aβ	topographies,	respectively.	Grey	regions	have	no	predictive	weight.	A:	Penalized	regression	models	that	predict	CSF	tau	and	Aβ42	using	tau	and	Aβ	topographies.	As	CSF	Aβ42	levels	are	inversely	related	to	amyloid	burden,	negative	weights	indicate	regions	where	topographies	predict	worse	CSF	Aβ42	pathology.	B:	Penalized	regression	
models	that	predict	neuropsychological	performance.	Regions	with	negative	values	are	where	more	PET	pathology	predicts	lower	cognitive	performance.		
